Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.[1][2][3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication.[4]
Clinical data | |
---|---|
Other names | BTRX-140; CYM-53093; NMRA-140; NMRA-335140 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H32FN5O2 |
Molar mass | 453.562 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ "BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders". BlackThorn Therapeutics. Archived from the original on 2020-01-25. Retrieved 2020-01-25.
- ^ "BTRX 335140 - AdisInsight". adisinsight.springer.com. Retrieved 2020-01-25.
- ^ Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019). "Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)". J. Med. Chem. 62 (4): 1761–1780. doi:10.1021/acs.jmedchem.8b01679. PMC 6395531. PMID 30707578.
- ^ Neumora Therapeutics, Inc. (2024-02-20). A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
External links
edit